Healthcare / Medical DevicesNasdaqCM
$2.41
+0.20 (+9.05%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 32% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-10.4M · quality 72.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
29/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$4M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-261.3%
↓Gross Margin
N/A
•Debt/Equity
0.13
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2011–2025 · 14 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
0.57x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-13.4M · FCF $-7.6M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||||||||
| Revenue | — | — | — | $574245.00 | $294165.00 | $659104.00 | $650187.00 | $229625.00 | $149625.00 | $392073.00 | $886572.00 | $762417.00 | $1.6M | $1.2M | $1.4M | — |
| Net Income | $-13.4M | $-13.4M | $-12.2M | $-12.0M | $-10.4M | $-7.9M | $-6.4M | $-6.2M | $-5.7M | $-7.3M | $-4.9M | $-6.8M | $-13.4M | $-4.9M | $-8.1M | $-5.7M |
| EBITDA | $-13.0M | $-13.0M | $-12.3M | $-11.7M | $-10.3M | $-7.9M | $-5.9M | $-6.0M | $-4.8M | $-6.1M | $-4.3M | $-4.0M | $-3.0M | $-3.6M | $-3.1M | $-4.5M |
| EPS | -8.58 | -8.58 | -388.80 | -47.20 | -56.80 | — | — | — | — | — | — | — | — | — | — | — |
| Operating Margin | — | — | — | -2072.0% | -3542.5% | -1197.3% | -912.0% | -2612.5% | -3228.8% | -1555.4% | -494.6% | -523.7% | -188.2% | -290.7% | -229.1% | — |
| Net Margin | — | — | — | -2094.9% | -3540.9% | -1196.6% | -980.3% | -2697.8% | -3795.9% | -1855.8% | -549.6% | -891.5% | -822.6% | -397.7% | -596.6% | — |
| Balance Sheet | ||||||||||||||||
| Debt/Equity | 0.13 | 0.13 | 0.16 | 0.08 | 0.04 | — | — | — | — | — | — | — | — | — | — | — |
| Current Ratio | 5.68 | 5.68 | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Cash Flow | ||||||||||||||||
| Free Cash Flow | $-7.6M | $-7.6M | $-10.4M | $-11.4M | $-10.1M | $-6.8M | $-5.3M | $-4.3M | $-3.9M | $-3.5M | $-4.3M | $-5.0M | $-2.2M | $-2.1M | $-1.8M | $-2.0M |
| Returns | ||||||||||||||||
| ROE | -261.3% | -261.3% | -211.7% | -79.9% | -60.8% | -83.6% | -67.7% | -255.4% | -92.6% | -1075.7% | -313.8% | -1104.4% | 89.4% | 53.5% | 87.3% | 95.6% |
| Valuation | ||||||||||||||||
| P/B | 0.73 | 0.73 | 7.63 | 5.18 | 10.85 | — | — | — | — | — | — | — | — | — | — | — |
| Growth & Yield | ||||||||||||||||
| Revenue Growth | — | — | — | 95.2% | — | 1.4% | 183.2% | 53.5% | -61.8% | -55.8% | 16.3% | -53.0% | 32.0% | -9.5% | — | — |
| EPS Growth | 97.8% | 97.8% | -723.7% | 16.9% | — | — | — | — | — | — | — | — | — | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-91.9%
Start / end P/E
n/dx → n/dx
EPS bridge
-388.80 → -8.58
Residual
-91.9%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.